Retroperitoneal lymphadenectomy in staging and treatment: The development of nerve-sparing techniques

J. P. Donohue, R. S. Foster

Research output: Contribution to journalArticle

63 Scopus citations


Currently, where available and widely practiced, nerve-sparing RPLND offers the least toxic and safest alternative in management of clinical stage I nerve-sparing germ cell tumor. Twenty-six percent to 30% of such cases are found to be node positive and, if no adjuvant chemotherapy is elected, two thirds do not relapse; those who do are uniformly rescued by chemotherapy. The 70% who are node negative have no long-term toxicity and do better in quality of life studies than their surveillance counterparts. Also, risk- benefit and cost-benefit studies support the competitive position of RPLND vis-a-vis the other options. Nonetheless, it is fair to say there are several options for management of clinical stage I nonseminomatous germ cell tumors that, when well applied, work well. Their choice depends on regional factors related to availability and experience.

Original languageEnglish (US)
Pages (from-to)461-468
Number of pages8
JournalUrologic Clinics of North America
Issue number3
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Retroperitoneal lymphadenectomy in staging and treatment: The development of nerve-sparing techniques'. Together they form a unique fingerprint.

  • Cite this